Press release
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market to Reach USD 2.3 Billion by 2034
Neurofibromatosis type 1 (NF1) is a rare, genetic tumor predisposition disorder caused by mutations in the NF1 gene. Among its manifestations, plexiform neurofibromas (PNs) are one of the most severe complications. These benign but often disfiguring and painful tumors can cause neurological impairment, airway obstruction, spinal deformities, and malignant transformation in rare cases.Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71719
Until recently, management relied on surgery, which is often risky and incomplete. The approval of MEK inhibitors has transformed the treatment landscape, offering the first targeted therapies for NF1-PN. Combined with genetic testing, patient advocacy, and growing clinical research, the NF1-PN market is set for strong expansion over the next decade.
Market Overview
• Market Size (2024): USD 1.05 billion
• Forecast (2034): USD 2.3 billion
• CAGR (2025-2034): 8.1%
The NF1-PN market is entering a growth phase as MEK inhibitors such as selumetinib (Koselugo) gain adoption, supported by global rare disease programs and increased clinical trial activity.
Key Highlights:
• Selumetinib is the first FDA- and EMA-approved therapy for NF1-PN.
• Strong pipeline of MEK inhibitors and other targeted therapies.
• Expanding genetic diagnostics improving early detection.
• Patient advocacy groups driving awareness and trial recruitment.
Segmentation Analysis
By Product Type:
• Targeted Therapies
o MEK Inhibitors (Selumetinib, Mirdametinib, Trametinib - pipeline/repurposed)
• Surgical Interventions
o Tumor Resection (limited use due to complexity)
• Supportive Care
o Pain Management
o Physiotherapy & Rehabilitation
• Genetic Testing & Counseling Services
By Platform:
• Small Molecules
• Biologics
• Genetic Testing Platforms
By Technology:
• Molecular Targeted Therapy Platforms
• AI-Driven Imaging & Tumor Monitoring
• Next-Gen Genetic Sequencing
By End Use:
• Hospitals
• Specialty Oncology & Neurology Clinics
• Research Institutes
• Genetic Counseling Centers
By Application:
• Pediatric NF1-PN Patients
• Adult NF1-PN Patients
• Clinical Research
Segmentation Summary:
Targeted therapies, led by MEK inhibitors, dominate the current market. Genetic testing and AI imaging technologies are expanding patient identification and monitoring, while supportive care remains essential in comprehensive management.
Explore Full Report here: https://exactitudeconsultancy.com/reports/71719/neurofibromatosis-type-1-associated-plexiform-neurofibromas-nf1-pn-market
Regional Analysis
North America
• Largest market with ~49% share in 2024.
• U.S. leads with FDA approval of selumetinib and strong insurance coverage for rare diseases.
• Well-developed patient registries and advocacy networks.
Europe
• Holds ~30% share.
• EMA approval of selumetinib driving adoption in Germany, UK, and France.
• Strong role of rare disease research initiatives and clinical trials.
Asia-Pacific
• Fastest-growing region with CAGR of ~9.4%.
• Japan, China, and India expanding genetic diagnostics and rare disease care.
• Growing clinical research participation and registry development.
Middle East & Africa
• Smaller market due to limited infrastructure.
• Gradual expansion of tertiary oncology centers.
Latin America
• Brazil and Mexico drive regional demand.
• Expanding access to MEK inhibitors and diagnostic tools.
Regional Summary:
North America and Europe dominate due to early therapy approvals and established rare disease frameworks, while Asia-Pacific represents the fastest growth opportunity with expanding awareness and healthcare access.
Market Dynamics
Key Growth Drivers:
• FDA/EMA approval of selumetinib creating a new treatment paradigm.
• Rising investment in MEK inhibitor pipelines.
• Expansion of genetic testing and counseling programs.
• Patient advocacy groups accelerating awareness and support.
Key Challenges:
• High cost of targeted therapies limiting access.
• Lifelong management required due to tumor recurrence risk.
• Limited availability of treatments in emerging economies.
• Small patient pool restricting large-scale commercial investment.
Latest Trends:
• Development of next-generation MEK inhibitors with improved tolerability.
• AI-assisted MRI for tumor growth monitoring.
• Research into combination regimens for NF1-PN management.
• Increasing collaboration between biotech firms and academic centers.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71719
Competitor Analysis
Major Players in the Market:
• AstraZeneca plc (Selumetinib/Koselugo)
• SpringWorks Therapeutics (Mirdametinib - pipeline)
• Novartis AG (Trametinib - repurposed research)
• Roche Holding AG
• Pfizer Inc.
• Bristol Myers Squibb (BMS)
• Eli Lilly and Company
• Amgen Inc.
• Illumina, Inc. (genetic diagnostics)
• Quest Diagnostics
Competitive Summary:
AstraZeneca leads the NF1-PN market with selumetinib, the first approved targeted therapy. SpringWorks is advancing mirdametinib in late-stage trials, while Novartis explores trametinib's potential. Diagnostics players like Illumina and Quest support patient identification. Competition is focused on next-gen MEK inhibitors, combination therapies, and global expansion.
Conclusion
The Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market, valued at USD 1.05 billion in 2024, is projected to reach USD 2.3 billion by 2034, growing at a CAGR of 8.1%. The market is being reshaped by targeted therapies, genetic diagnostics, and patient advocacy, offering new hope to patients worldwide.
Key Takeaways:
• Selumetinib has established a new treatment standard for NF1-PN.
• North America and Europe dominate, while Asia-Pacific grows fastest.
• Genetic testing and AI imaging are improving diagnosis and monitoring.
• Next-gen MEK inhibitors and combination regimens represent the future.
The next decade will see NF1-PN management evolve from surgical reliance to precision-targeted therapies and AI-driven monitoring, creating strong opportunities for pharmaceutical innovators, diagnostics firms, and healthcare providers.
This report is also available in the following languages : Japanese (神経線維腫症1型関連叢状神経線維腫(NF1-PN)市場), Korean (1형 신경섬유종증 관련 총상신경섬유종(NF1-PN) 시장), Chinese (1 型神经纤维瘤病相关丛状神经纤维瘤 (NF1-PN) 市场), French (Marché des neurofibromes plexiformes associés à la neurofibromatose de type 1 (NF1-PN)), German (Markt für plexiforme Neurofibrome (NF1-PN) im Zusammenhang mit Neurofibromatose Typ 1), and Italian (Mercato dei neurofibromi plessiformi associati alla neurofibromatosi di tipo 1 (NF1-PN)), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71719/neurofibromatosis-type-1-associated-plexiform-neurofibromas-nf1-pn-market#request-a-sample
Our More Reports:
North America Non-Vascular Stents Market
https://exactitudeconsultancy.com/reports/72348/north-america-non-vascular-stents-market
EU5 Hernia Repair Devices Market
https://exactitudeconsultancy.com/reports/72349/eu5-hernia-repair-devices-market
BRIC Hernia Repair Devices Market
https://exactitudeconsultancy.com/reports/72350/bric-hernia-repair-devices-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market to Reach USD 2.3 Billion by 2034 here
News-ID: 4177698 • Views: …
More Releases from Exactitude Consultancy

Current study on mesenchymal stem cell exosome therapy's potential to reverse no …
The global Exosome Therapy Market is emerging as a transformative frontier in regenerative medicine, precision diagnostics, and targeted drug delivery. Exosomes, nanosized extracellular vesicles secreted by cells, are now recognized as powerful mediators of intercellular communication, capable of influencing tissue regeneration, immune modulation, and disease progression. Over the past decade, interest in exosome-based therapies has grown rapidly, with applications spanning oncology, neurology, cardiology, dermatology, and orthopedics. By 2034, the exosome…

A 'Silver Lining' for Ascending Thoracic Aortic Aneurysms
Introduction
A thoracic aortic aneurysm (TAA) is a serious cardiovascular condition characterized by abnormal dilation of the aorta within the chest, which can lead to life-threatening complications if left untreated, including dissection and rupture. Risk factors include hypertension, atherosclerosis, connective tissue disorders, and genetic syndromes such as Marfan and Loeys-Dietz.
Although TAAs are relatively rare compared to abdominal aortic aneurysms, they carry high morbidity and mortality risks. Early detection through imaging and…

For the targeted treatment of localized prostate cancer, photodynamic therapy
Introduction
Photodynamic therapy (PDT) is an innovative, minimally invasive treatment that combines photosensitizing agents, oxygen, and light to selectively destroy abnormal or cancerous cells. Originally developed for dermatological conditions, PDT has rapidly expanded into oncology, ophthalmology, and infectious diseases, offering a targeted therapy with fewer side effects compared to chemotherapy and radiation.
The rising prevalence of cancer, non-melanoma skin disorders, and antimicrobial resistance has made PDT an increasingly attractive therapeutic option. Over…

From mechanism of action to prospective immunotherapeutic methods, TIGIT in canc …
Introduction
The field of immuno-oncology has revolutionized cancer treatment, with checkpoint inhibitors such as PD-1, PD-L1, and CTLA-4 therapies transforming outcomes for patients with advanced malignancies. However, many patients still fail to respond or develop resistance, underscoring the need for new immune checkpoint targets. T-cell immunoreceptor with Ig and ITIM domains (TIGIT) has emerged as one of the most promising next-generation targets, showing strong potential to enhance anti-tumor immunity when combined…
More Releases for NF1
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market Pois …
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market Summary
NF1-PN Market Set to Grow Beyond USD 380 Million by 2034 driven by rising diagnosed cases, better awareness, advanced diagnostics, and genetic testing. In the US alone, ~97,000 diagnosed NF1 cases were reported in 2023, expected to increase by 2034. Treatment remains challenging-surgery is often complex, risky, and prone to recurrence, leaving significant unmet needs, especially in pediatric patients with inoperable PNs. Current…
Neurofibromatosis Type 1 Treatment Landscape: FDA Expands KOSELUGO Approval to Y …
DelveInsight Business Research's analysis underscores the transformative impact of the FDA's September 10, 2025 approval of KOSELUGO (selumetinib) granules and capsules for pediatric patients aged 1 year and older with symptomatic, inoperable plexiform neurofibromas (PN) associated with Neurofibromatosis Type 1 (NF1). This expansion marks the first therapy targeting NF1-PN in this younger age group, offering hope to ~97,000 diagnosed children in the US.
Key NF1 Market Highlights
*
The Neurofibromatosis Type 1 treatment…
Neurofibromatosis Type 1 (NF1) Market to Reach USD 2.5 Billion by 2034
Neurofibromatosis Type 1 (NF1) is one of the most common genetic disorders among rare diseases, affecting approximately 1 in 3,000 individuals worldwide. It is caused by mutations in the NF1 gene, which encodes neurofibromin, a protein that helps regulate cell growth. Patients with NF1 develop benign tumors along nerves, skin abnormalities, and in some cases, malignant peripheral nerve sheath tumors (MPNSTs).
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71663
Historically,…
The NF1-PN Market Size in 7MM to Witness Notable Growth, Expanding from USD 380 …
The the emergence of new transformative NF1-PN treatments such as KOSELUGO (AstraZeneca and Merck), Mirdametinib (SpringWorks Therapeutics), HLX-1502 (Healx), FCN-159 (Fosun Pharmaceutical), and AS-004 (Pasithea Therapeutics), and others.
The Neurofibromatosis type 1-associated Plexiform Neurofibromas market across the 7MM is expected to surge owing to an increased awareness, advancements in diagnostic techniques, greater accessibility to genetic testing, and the emergence of new transformative treatments such as KOSELUGO (AstraZeneca and Merck), Mirdametinib (SpringWorks…
In-Depth Analysis of the Neurofibromatosis Type 1 Market: Growth Opportunities, …
What industry-specific factors are fueling the growth of the neurofibromatosis type 1 market?
The rising occurrence of spontaneous (de novo) mutations is expected to boost the growth of the neurofibromatosis type 1 (NF1) market. Spontaneous mutations occur due to errors in DNA replication or environmental factors, rather than being inherited. In NF1, the high mutation rate in the NF1 gene contributes to new cases, even without a family history. For example,…
The NF1-PN Market in 7MM to Witness Notable Growth, Expanding from USD 380 milli …
The ongoing NF1-PN drug development pipeline features additional MEK inhibitors, including Mirdametinib (SpringWorks Therapeutics), FCN-159 (Fosun Pharmaceutical), and PAS-004 (Pasithea Therapeutics). Additionally, HLX-1502 (Healx) is an emerging investigational therapy that provides a novel treatment approach for NF1 patients.
The Neurofibromatosis type 1-associated Plexiform Neurofibromas market across the 7MM is expected to surge owing to an increased awareness, advancements in diagnostic techniques, greater accessibility to genetic testing, and the emergence of new…